US Patent Issued to St. Jude Children's Research Hospital, National University of Singapore on Aug. 4 for "Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease" (Singaporean, Taiwanese Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,476, issued on Aug. 4, was assigned to St. Jude Children's Research Hospital Inc. (Memphis, Tenn.) and National University of Singapore (Singapore).

"Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease" was invented by Dario Campana (Singapore) and Yu-Hsiang Chang (Kaohsiung City, Taiwan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encom...